The global antiviral drugs market is witnessing steady growth, driven by the increasing prevalence of viral infections, rising awareness of antiviral treatments, and advancements in drug development. The market is supported by ongoing research and development efforts, leading to the introduction of innovative antiviral therapies targeting a broad spectrum of viruses. Additionally, government initiatives, collaborations between pharmaceutical companies, and the expansion of healthcare infrastructure contribute to market expansion. The market remains competitive, with key players focusing on strategic partnerships, product approvals, and technological advancements to strengthen their market position.
Global Antiviral Drugs Market is expected to reach USD 107.70 billion by 2030, with a growing CAGR of 5.5% during the forecast period 2023 to 2030.
To know more, visit https://www.databridgemarketresearch.com/reports/global-antiviral-drugs-market
Below are the Top Antiviral Drugs Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Gilead Sciences, Inc.
|
Gilead Sciences is a leading biopharmaceutical company specializing in antiviral drugs, particularly for HIV, hepatitis B & C, and influenza. In the antiviral drugs market, Gilead dominates with its blockbuster drug Remdesivir (Veklury), which was widely used for treating COVID-19. The company also has a strong portfolio of HIV antivirals, including Biktarvy, Truvada, and Descovy.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
|
|
2.
|
Pfizer Inc.
|
Pfizer has a significant presence in the antiviral market, primarily due to the success of Paxlovid (nirmatrelvir/ritonavir), an oral antiviral treatment for COVID-19. Additionally, the company has a history of antiviral drug development for conditions such as HIV and hepatitis C. Its strategic partnerships and R&D investments continue to expand its antiviral drug pipeline.
|
|
America, Middle East and Africa, Asia-Pacific, and Europe
|
In December 2021, Pfizer Inc. announced the U.S. Food and Drug Administration (FDA) had authorized the emergency use of PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing.
|
|
3.
|
SIGA Technologies
|
SIGA Technologies focuses on antiviral therapeutics, particularly for smallpox and orthopoxvirus infections. The company’s key antiviral product is TPOXX (tecovirimat), the first FDA-approved treatment for smallpox. It is also being explored for monkeypox and other orthopoxvirus infections, making SIGA a key player in bioterrorism and pandemic preparedness efforts.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2022, SIGA Technologies announced that they set out to make a smallpox therapy in case the eradicated virus was ever used as a bioweapon. U.S. regulators approved the resulting oral antiviral, TPOXX (tecovirimat), largely based on the animal study. This will help the company in product expansion.
|
|
4.
|
GlaxoSmithKline plc.
|
GSK is a major player in the antiviral market, with a strong focus on influenza, HIV, and respiratory viruses. Its antiviral portfolio includes Xofluza (baloxavir marboxil) for influenza and HIV treatments developed in partnership with ViiV Healthcare, such as Dolutegravir (Tivicay) and Cabotegravir (Apretude). GSK also played a role in developing COVID-19 monoclonal antibody treatments.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In December 2021, GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) had granted conditional marketing authorization for Xevudy (sotrovimab) for the treatment of symptomatic adults and adolescents (aged 12 years and over and weighing at least 40 kg) with acute COVID-19 infection who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID infection
|
|
5.
|
F. Hoffmann-La Roche Ltd
|
Roche has a robust presence in the antiviral segment, primarily through its well-established influenza treatment Tamiflu (oseltamivir). The company has also been involved in COVID-19 antiviral research and collaborates with various partners to develop new therapies targeting viral infections.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In December 2021, F. Hoffmann-La Roche Ltd announced that it completed the repurchase of Roche shares that Novartis had held. Roche and Novartis had announced this repurchase. The repurchase will help in the growth of the revenue of F. Hoffmann-La Roche Ltd.
|
Conclusion
The global antiviral drugs market is poised for continued expansion, driven by the growing burden of viral diseases and the increasing demand for effective treatment options. Continuous innovation and investment in antiviral research are expected to enhance the efficacy and accessibility of treatments, further fueling market growth. Despite potential hurdles such as regulatory challenges and drug resistance, the industry is likely to benefit from advancements in biotechnology and an increasing focus on pandemic preparedness. Key market players will play a crucial role in shaping the competitive landscape through strategic initiatives, ensuring sustained growth in the coming years.
